Influences of Propofol and Sevoflurane Anesthesia in Ovarian Cancer (Anesthetics)

Last updated: May 26, 2023
Sponsor: Kaohsiung Medical University Chung-Ho Memorial Hospital
Overall Status: Active - Recruiting

Phase

4

Condition

Pelvic Cancer

Ovarian Cysts

Ovarian Cancer

Treatment

Propofol 1%

Sevoflurane/Ultane

Clinical Study ID

NCT05606692
KMUHIRB-F(II)-20220157
  • Ages 20-80
  • Female

Study Summary

Ⅶ. Study procedures (summary)

  1. Written informed consent must be obtained before any study specific procedures are undertaken.

    Qualified participants were identified at the pre-anesthesia evaluation clinic or ward. The informed consents are obtained from the patient in the ward at night before the operation.

  2. The process of the experiment (brief describe) In the preoperative waiting area, the patients are randomly assigned and divided into two groups according to the allocation sequence table (corresponding to 1:1 randomization) generated by the computer. The propofol group was both induced and maintained at an effect-site concentration (Ce) of 2.0-4.0 mcg/mL by a target-controlled infusion (TCI) system. The sevoflurane group was maintained via sevoflurane vaporizer between 1% and 3% (target minimum alveolar concentration of 0.7-1.3). During the operation, the dose of anesthetic drugs (propofol/fentanyl /remifentanil and sevoflurane/cisatracurium/rocuronium) are adjusted to maintain the mean arterial pressure and heartbeat fluctuations within 20% of the baseline value and Entropy (or BIS) value at 40-60in both groups. The following patient data were recorded, the type of anesthesia, sex, age at the time of surgery, preoperative Karnofsky performance status (KPS) score and functional capacity, the postoperative complications within 30 days (according Clavien-Dindo classification), ASA physical status scores, tumor marker ,tumor size, intraoperative blood loss/transfusion, duration of surgery, duration of anesthesia, total opioid (remifentanil/fentanyl) use, postoperative radiation therapy, postoperative chemotherapy, postoperative concurrent chemoradiotherapy, the presence of disease progression, and 6-month, 1-year, 3-year and 5-year overall survival and Karnofsky performance status score were recorded.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  1. Twenty to eighty-year-old.
  2. ASA class I-III.
  3. Patients undergoing elective craniotomy for primary ovarian tumors under generalanesthesia.

Exclusion

Exclusion Criteria:

  1. Severe mental disorder
  2. Poor liver function
  3. Pregnant or lactating women
  4. Morbid obesity
  5. Have a history of allergy to any drug used in this study
  6. Non-primary ovarian cancer surgery
  7. Undergoing ovarian cancer pathological section surgery
  8. Patients with incomplete medical records
  9. Combined with other surgeries, emergency surgeries
  10. Concomitant patients with other non-ovarian cancer therapy
  11. Patients receiving palliative treatment after ovarian cancer surgery
  12. During the maintenance period of anesthesia, propofol or sevoflurane should not beused as anesthetic drugs
  13. Intraoperative combined use of multiple anesthetics (such as ketamine,dexmedetomidine, other inhalation anesthetics)
  14. Those diagnosed with benign tumors before and after surgery
  15. Patients with metastases to the ovary

Study Design

Total Participants: 416
Treatment Group(s): 2
Primary Treatment: Propofol 1%
Phase: 4
Study Start date:
November 23, 2022
Estimated Completion Date:
September 30, 2027

Study Description

During the operation, the dose of anesthetic drugs (propofol/ fentanyl /remifentanil and sevoflurane/ cisatracurium/ rocuronium) are adjusted to maintain the mean arterial pressure and heartbeat fluctuations within 20% of the baseline value and Entropy (or BIS) value at 40-60in both groups. The following patient data were recorded, the type of anesthesia, age at the time of surgery, preoperative Karnofsky performance status (KPS) score and functional capacity, the postoperative complications within 30 days (according Clavien-Dindo classification), ASA physical status scoress, tumor marker , tumor size, intraoperative blood loss/transfusion, duration of surgery, duration of anesthesia, total opioid (remifentanil/ fentanyl/ propofol) use, postoperative radiation therapy, postoperative chemotherapy, postoperative concurrent chemoradiotherapy, the presence of disease progression, and 6-month, 1-year, and 3-year overall survival and Karnofsky performance status score were recorded.

Connect with a study center

  • Kaohsiung Medical University Chung-Ho Memorial Hospital

    Kaohsiung,
    Taiwan

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.